# Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19

> **NCT04527575** · PHASE1,PHASE2 · COMPLETED · sponsor: **Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"** · enrollment: 100 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)
- **OTHER:** Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%)

## Key facts

- **NCT ID:** NCT04527575
- **Lead sponsor:** Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-27
- **Primary completion:** 2021-12-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2022-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04527575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04527575, "Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04527575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*